Neuland Laboratories (NSE:NEULANDLAB) Operating Income: ₹4,828 Mil (TTM As of Mar. 2026)


NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
90 GF Score
Price ₹19,506.00
GF Value ₹16,036.83
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Neuland Laboratories Operating Income?

Neuland Laboratories NSE:NEULANDLAB -0.18% 90 Operating Income is ₹4,828 Mil as of Mar. 2026. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 90/100 and a GF Value™ of ₹16,036.83 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Neuland Laboratories's Operating Income for the three months ended in Mar. 2026 was ₹2,822 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4,828 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Neuland Laboratories's Operating Income for the three months ended in Mar. 2026 was ₹2,822 Mil. Neuland Laboratories's Revenue for the three months ended in Mar. 2026 was ₹7,763 Mil. Therefore, Neuland Laboratories's Operating Margin % for the quarter that ended in Mar. 2026 was 36.36%.

Good Sign:

Neuland Laboratories Ltd operating margin is expanding. Margin expansion is usually a good sign.

Neuland Laboratories's 5-Year average Growth Rate for Operating Margin % was 16.30% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Neuland Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 36.55%. Neuland Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 72.85%.


Neuland Laboratories  (NSE:NEULANDLAB) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Neuland Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=11289.668 * ( 1 - 26.03% )/( (0 + 22847.225)/ 1 )
=8350.9674196/22847.225
=36.55 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=29301.377 - 3187.448 - ( 3266.704 - max(0, 7101.98 - 14831.288+3266.704))
=22847.225

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Neuland Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=11787.996/( ( (0 + max(0, 0)) + (11429.977 + max(4751.486, 0)) )/ 1 )
=11787.996/( ( 0 + 16181.463 )/ 1 )
=11787.996/16181.463
=72.85 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5413.531 + 5102.864 + 930.77) - (3187.448 + 0 + 3508.231)
=4751.486

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Neuland Laboratories's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=2822.417/7762.503
=36.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Neuland Laboratories Operating Income Related Terms


Neuland Laboratories Operating Income Historical Data

* Premium members only.

The historical data trend for Neuland Laboratories's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuland Laboratories Operating Income Chart

Neuland Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 960.90 2,343.41 4,073.82 2,665.78 4,900.24

Neuland Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 341.82 142.99 1,330.04 532.13 2,822.42
NSE:NEULANDLAB
90GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuland Laboratories Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,828 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of ₹4,828 Mil mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Operating Income of ₹4,828 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Neuland Laboratories and its competitors.
Is Neuland Laboratories' Operating Income too high?
Neuland Laboratories' current Operating Income is ₹4,828 Mil. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Operating Income compare to ZTS and UTHR?
Neuland Laboratories' Operating Income of ₹4,828 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Neuland Laboratories and its competitors. Neuland Laboratories's current Operating Income is ₹4,828 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,036.83, compared to a current price of ₹19,506.00 — trading 21.6% above its estimated fair value. The current Operating Income is ₹4,828 Mil. Neuland Laboratories' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Operating Income is ₹4,828 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹19,506.00 is trading 21.6% above its estimated GF Value™ of ₹16,036.83. GuruFocus considers Neuland Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:NEULANDLAB:

  • Operating Income: ₹4,828 Mil
  • GF Value™: ₹16,036.83 vs. price of ₹19,506.00 (21.6% above fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score

Get the complete analysis for NSE:NEULANDLAB

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹19,506.00
Price
₹16,036.83
GF Value